What is the difference between Mounjaro and Zepbound?

Mounjaro and Zepbound both contain tirzepatide, manufactured by Eli Lilly. Mounjaro received FDA approval in 2022 for type 2 diabetes management. Zepbound, approved in late 2023, is the same medication but branded specifically for chronic weight management. Both activate GLP-1 and GIP receptors (dual agonist), making them more potent than single-agonist GLP-1 medications like semaglutide. Clinical trials show tirzepatide produces 15-22% weight loss on average. The main distinction is marketing and FDA indication - Mounjaro for diabetes, Zepbound for obesity treatment.